Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients

Next Previous
Trial Profile

A Phase III, Randomized, Double-blind, Placebo-controlled Study of AeroVanc for the Treatment of Persistent Methicillin-resistant Staphylococcus Aureus Lung Infection in Cystic Fibrosis Patients

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vancomycin (Primary)
  • Indications Methicillin-resistant Staphylococcus aureus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms AVAIL
  • Sponsors Savara Pharmaceuticals

    • Most Recent Events

    • 10 Dec 2020 According to a Savara Pharmaceuticals media release, based on the AVAIL results, the company is discontinuing further development of AeroVanc.
    • 10 Dec 2020 Primary endpoint (The mean absolute change from baseline in FEV1 percent predicted.The endpoint will be analyzed sequentially at week 12 (the end of cycle 2)) has not been met, according to a Savara Pharmaceuticals media release.
    • 10 Dec 2020 Primary endpoint (The mean absolute change from baseline in FEV1 percent predicted.The endpoint will be analyzed sequentially at Week 4 (end of Cycle 1) and at Week 20 (end of Cycle 3)) has not been met, according to a Savara Pharmaceuticals media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top